This article is more than 5 years old. Information may no longer be current.

Higher dose squalamine enters phase 2 trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PLYMOUTH MEETING, Pa. — A phase 2 trial to determine efficacy and safety of squalamine lactate at higher doses is under way, the drug’s developer said in a press release. The study will evaluate up to 140 patients with wet age-related macular degeneration over a 20-week period.

Genaera said the trial will compare 40, 80, 120 and 160 mg of Evizon (squalamine) in a multicenter trial. The study “will provide more detailed information on Evizon’s effects on visual acuity in both affected eyes of patients with exudative AMD,” said Jack Armstrong, Genaera’s president and chief executive officer.

Evizon is administered intravenously rather than intravitreally.